Teva online shopping search
Simply find the best possible online shopping Teva deals
Teva shopping marketplace results
Shop Teva products and compare prices and listings on popular online marketplaces.
Teva video reviews
Teva news
Teva - BingNovice
Teva’s TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trial
About 80% of patients with schizophrenia who received TEV-‘749 in the SOLARIS Phase 3 trial achieved clinical stabilization, according to post hoc data Teva presented this week, and that stabilization held across longer follow-up in the open-label extension. That number matters because stabilization is the threshold patients and clinicians actually care about in a maintenance setting, and it is harder to sustain than a statistically significant symptom score at week eight.
The SOLARIS trial tested TEV-‘749, a once-monthly subcutaneous formulation of olanzapine, in adults aged 18 to 64 with schizophrenia. The study ran an eight-week randomized, double-blind, placebo-controlled period before moving patients into an open-label extension where the durability data accumulated. The post hoc analyses Teva released this week also examined switching strategies, which tells you the commercial target: patients already on oral olanzapine or another antipsychotic who are candidates for a long-acting injectable but whose clinicians want a transition roadmap before committing.
The subcutaneous route is the design choice that separates TEV-‘749 from the existing olanzapine LAI on the market. Zyprexa Relprevv, approved in 2009, is an intramuscular formulation and carries a boxed warning for post-injection delirium sedation syndrome, a rare but serious reaction that required patients to…
Teva launches new global innovation program, will fully fund startup pilots
On Tuesday, Teva published its open call and defined the areas in which it is seeking solutions. Companies developing human-based models for testing biologic drugs as an alternative to animal experiments, AI-based tools for clinical trial simulation and design, or technologies that improve patient experience and adherence to long-acting injectable treatments are among those Teva hopes to attract.
Teva
(Photo: Sivan Farage)
Beyond healthcare, Teva is also looking for advanced analytics for bid optimization, predictive maintenance tools for equipment and assets, systems for product quality and risk forecasting, and technologies that optimize manufacturing resource allocation. These fields comprise the seven innovation domains the company is targeting.
Yossi Ofek, Teva Israel’s CEO and cluster head for Ukraine, Africa and the Middle East, told ynet that the Rise platform reflects Teva’s strategic shift toward entrepreneurial thinking. “More resources are going toward developing innovative medicines,” he…
Teva präsentiert Psychiatrie-Daten: UZEDY senkt Notfallkosten, TEV-749 stärkt Pipeline
Goldesel Kompakt
Das Wichtigste in Kürze
-
01
Teva präsentierte beim Psych Congress neue Real-World-Daten zu UZEDY bei Schizophrenie und bipolarer-I-Störung.
-
02
UZEDY senkte in einer Vergleichsanalyse die Rate allgemeiner Notaufnahmebesuche um 40 Prozent und die monatlichen direkten Gesundheitskosten um 1.036,70 US-Dollar je Patient.
-
03
Gegenüber mehreren langwirksamen Antipsychotika zeigte UZEDY höhere Therapietreue und eine geringere Abbruchwahrscheinlichkeit.
-
04
Post-hoc-Daten aus der SOLARIS-Phase-3-Studie stützen die langfristige Wirksamkeit und Stabilität von TEV-749, einer monatlichen Olanzapin-Injektion.
Marktanalyse & Details
UZEDY mit Vorteilen bei Notfallversorgung und Kosten
Teva stellte die neuen Ergebnisse vom 15. bis 19. September 2026 beim Psych Congress in New Orleans vor. Im Mittelpunkt standen Real-World-Analysen zur einmal monatlichen Depotformulierung UZEDY bei Erwachsenen mit Schizophrenie und bipolarer-I-Störung.
In einer gematchten Kohorte mit 1.166 Patienten entfiel auf 22,0 Prozent der UZEDY-Behandelten mindestens ein Besuch in der Notaufnahme. Bei Patienten unter einmal monatlich verabreichtem Paliperidonpalmitat lag der Anteil bei 27,8 Prozent. Die Rate aller Notaufnahmebesuche war bei UZEDY insgesamt um 40 Prozent niedriger. Auch stationäre Einweisungen traten numerisch seltener auf: 11,1 Prozent gegenüber 14,8 Prozent.
Der wirtschaftliche Unterschied fiel ebenfalls deutlich aus. Die geschätzten direkten Gesundheitskosten pro Monat betrugen unter UZEDY durchschnittlich 4.688,10 US-Dollar, verglichen mit 5.724,80 US-Dollar bei Paliperidonpalmitat. Daraus ergab sich eine…